Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibezapolstat - Acurx Pharmaceuticals

Next Previous
Drug Profile

Ibezapolstat - Acurx Pharmaceuticals

Alternative Names: 362E; ACX-362E; GLS-362E; MorE-DCBG

Latest Information Update: 03 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GLSynthesis
  • Developer Acurx Pharmaceuticals
  • Class Antibacterials; Chlorobenzenes; Morpholines; Purines; Pyrimidines; Small molecules
  • Mechanism of Action DNA polymerase III inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Clostridium difficile infections

Most Recent Events

  • 19 Feb 2025 Acurx Pharmaceuticals announces intention to submit MAA to EMA for Clostridium difficile infections
  • 06 Jan 2025 Acurx Pharmaceuticals plans a phase III trial for Clostridium difficile infections (PO), in the year 2025
  • 06 Jan 2025 Acurx receives positive regulatory guidance from EMA for phase III program for Clostridium difficile infections

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top